Risk factors for CNS relapse in transformed WM
| Variable . | Cumulative incidence at 3 y . | Univariate model . | |||||
|---|---|---|---|---|---|---|---|
| With . | Without . | ||||||
| % . | 95% CI . | % . | 95% CI . | SHR . | 95% CI . | P . | |
| Age > 60 | 13 | 8-19 | 4 | 8-13 | 1.70 | 0.59-4.87 | .32 |
| Female sex | 11 | 5-20 | 10 | 6-17 | 0.89 | 0.38-2.09 | .80 |
| Treatment prior to HT | 10 | 6-16 | 11 | 4-22 | 0.75 | 0.31-1.80 | .51 |
| ECOG PS 2-4 | 9 | 3-18 | 11 | 6-18 | 0.82 | 0.33-2.00 | .66 |
| B symptoms | 10 | 5-18 | 11 | 6-19 | 0.73 | 0.30-1.76 | .48 |
| LDH > ULN | 10 | 5-16 | 9 | 3-19 | 0.78 | 0.32-1.89 | .58 |
| β2 microglobulin >3 mg/L | 17 | 8-27 | 6 | 3-23 | 1.17 | 0.34-4.00 | .81 |
| Albumin <3.5 g/dL | 8 | 3-15 | 12 | 5-21 | 0.46 | 0.17-1.23 | .12 |
| Stage III-IV | 12 | 7-18 | 6 | 10-17 | 1.74 | 0.53-5.69 | .36 |
| ≥2 extranodal sites | 21 | 10-35 | 8 | 6-24 | 2.28 | 0.98-5.30 | .06 |
| Extranodal involvement | |||||||
| Kidney/adrenal | 36 | 10-65 | 9 | 5-14 | 4.36 | 1.39-13.72 | .01 |
| Testis | 0 | NA | 11 | 7-16 | 0.90 | 0.14-5.94 | .91 |
| Bone marrow | 17 | 9-28 | 7 | 4-13 | 1.99 | 0.88-4.49 | .10 |
| Liver | 17 | 2-43 | 10 | 6-15 | 1.48 | 0.33-6.66 | .61 |
| Skin | 13 | 2-34 | 10 | 6-16 | 1.02 | 0.24-4.30 | .98 |
| MYD88L265P mutation | 17 | 8-30 | 0 | NA | .01 | ||
| CNS-IPI | |||||||
| Low risk (0-1) | 0 | NA | ref. | .47 | |||
| Intermediate risk (2-3) | 9 | 4-16 | 2.03 | 0.28-14.6 | |||
| High risk (4-6) | 14 | 6-24 | 2.99 | 0.41-21.92 | |||
| Variable . | Cumulative incidence at 3 y . | Univariate model . | |||||
|---|---|---|---|---|---|---|---|
| With . | Without . | ||||||
| % . | 95% CI . | % . | 95% CI . | SHR . | 95% CI . | P . | |
| Age > 60 | 13 | 8-19 | 4 | 8-13 | 1.70 | 0.59-4.87 | .32 |
| Female sex | 11 | 5-20 | 10 | 6-17 | 0.89 | 0.38-2.09 | .80 |
| Treatment prior to HT | 10 | 6-16 | 11 | 4-22 | 0.75 | 0.31-1.80 | .51 |
| ECOG PS 2-4 | 9 | 3-18 | 11 | 6-18 | 0.82 | 0.33-2.00 | .66 |
| B symptoms | 10 | 5-18 | 11 | 6-19 | 0.73 | 0.30-1.76 | .48 |
| LDH > ULN | 10 | 5-16 | 9 | 3-19 | 0.78 | 0.32-1.89 | .58 |
| β2 microglobulin >3 mg/L | 17 | 8-27 | 6 | 3-23 | 1.17 | 0.34-4.00 | .81 |
| Albumin <3.5 g/dL | 8 | 3-15 | 12 | 5-21 | 0.46 | 0.17-1.23 | .12 |
| Stage III-IV | 12 | 7-18 | 6 | 10-17 | 1.74 | 0.53-5.69 | .36 |
| ≥2 extranodal sites | 21 | 10-35 | 8 | 6-24 | 2.28 | 0.98-5.30 | .06 |
| Extranodal involvement | |||||||
| Kidney/adrenal | 36 | 10-65 | 9 | 5-14 | 4.36 | 1.39-13.72 | .01 |
| Testis | 0 | NA | 11 | 7-16 | 0.90 | 0.14-5.94 | .91 |
| Bone marrow | 17 | 9-28 | 7 | 4-13 | 1.99 | 0.88-4.49 | .10 |
| Liver | 17 | 2-43 | 10 | 6-15 | 1.48 | 0.33-6.66 | .61 |
| Skin | 13 | 2-34 | 10 | 6-16 | 1.02 | 0.24-4.30 | .98 |
| MYD88L265P mutation | 17 | 8-30 | 0 | NA | .01 | ||
| CNS-IPI | |||||||
| Low risk (0-1) | 0 | NA | ref. | .47 | |||
| Intermediate risk (2-3) | 9 | 4-16 | 2.03 | 0.28-14.6 | |||
| High risk (4-6) | 14 | 6-24 | 2.99 | 0.41-21.92 | |||
CNS-IPI, central nervous system-International Prognostic Index; ECOG PS, Eastern Cooperative Oncology Group performance status; HT, histological transformation; SHR, sub-hazard ratio; ULN, upper limit of normal.